Pharmacokinetics and selected pharmacodynamic effects of tramadol following intravenous administration to the horse.
Authors: Knych H K, Corado C R, McKemie D S, Steffey E P
Journal: Equine veterinary journal
Summary
# Editorial Summary: Tramadol Pharmacokinetics in the Horse Tramadol's analgesic potential in equine medicine remains incompletely understood, with conflicting reports about how horses metabolise and respond to the drug, prompting Knych and colleagues to characterise its pharmacokinetic profile and selected pharmacodynamic effects across three dosing regimens. Nine horses received intravenous tramadol at 0.5, 1.5 and 3 mg/kg bodyweight, with plasma samples analysed up to 72 hours post-administration using liquid chromatography-mass spectrometry; researchers also monitored stride length, cardiac parameters, step count and gastrointestinal motility. Peak plasma concentrations increased dose-dependently (454–1,698 ng/ml), whilst the drug displayed consistent clearance (24.6–25.0 ml/min/kg), volume of distribution (2.66–3.33 l/kg) and elimination half-life (2.17–3.05 hours) regardless of dose; active metabolite O-desmethyltramadol accumulated at substantially lower concentrations than the parent compound. Muscle fasiculations and tremors occurred at higher doses, yet no observable changes in gait, cardiac function or GI activity were recorded—findings suggesting tramadol concentrations exceeded those required for analgesia in humans, though equine analgesic thresholds remain unknown. For practitioners considering tramadol for pain management, these data establish a pharmacokinetic foundation but underscore the critical need for clinical efficacy trials to determine whether achievable plasma concentrations actually translate to therapeutic analgesia in horses.
Read the full abstract on PubMed
Practical Takeaways
- •Tramadol achieves plasma concentrations in horses that exceed those needed for analgesia in humans, but analgesic efficacy in horses remains unproven and requires further clinical investigation
- •Higher tramadol doses (≥1.5 mg/kg IV) produce neuromuscular side effects (fasciculations and tremors) that warrant monitoring during clinical use
- •The relatively short half-life (2–3 hours) suggests frequent dosing intervals may be needed if tramadol is used for pain management in equine practice
Key Findings
- •Tramadol clearance ranged from 24.6–25.0 ml/min/kg and half-life from 2.17–3.05 h across three dose levels (0.5–3 mg/kg)
- •Peak plasma tramadol concentrations of 454–1698 ng/ml were achieved across doses, exceeding human analgesic thresholds
- •Active metabolite O-desmethyltramadol reached maximal concentrations of 3.9–12.9 ng/ml depending on dose
- •Muscle fasciculations and tremors observed at higher doses (1.5 and 3 mg/kg); no significant effects on gait, heart rate, or gastrointestinal activity